Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Rege Nephro Co. Ltd. is currently navigating 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, ensuring that each matter receives an independent review. MATALKAH, FATIMAH KHALAF is identified as the busiest examiner for the portfolio, currently overseeing 1 pending office action.
The prosecution is spread across 2 distinct art units, which matches the number of examiners and pending actions. This distribution indicates that the company's biotechnology filings are technically diverse enough to be assigned to different specialized groups within the patent office. With 2 distinct examiners involved, the company must manage two separate sets of examiner expectations and procedural interpretations.
The presence of 2 pending office actions across 2 distinct art units suggests a balanced but small portfolio. Because the busiest examiner, MATALKAH, FATIMAH KHALAF, handles only 1 pending office action, no single individual has a dominant influence over the company's current outcomes. This structure requires the company to maintain a flexible strategy that can adapt to the different styles of 2 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATALKAH, FATIMAH KHALAF | 1 | 55.8% | +27.4% |
| O'NEILL, MARISOL ANN | 1 | 54.5% | +68.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271112 | MEDIUM FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, METHOD FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, AND METHOD FOR PRODUCING RENAL ORGANOIDS | O'NEILL, MARISOL ANN | 21d |
| 18682870 | METHOD FOR PRODUCING RENAL INTERSTITIAL PROGENITOR CELLS, ERYTHROPOIETIN-PRODUCING CELLS, AND METHOD FOR PRODUCING RENIN-PRODUCING CELLS | MATALKAH, FATIMAH KHALAF | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271112 | MEDIUM FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, METHOD FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, AND METHOD FOR PRODUCING RENAL ORGANOIDS | O'NEILL, MARISOL ANN | 21d |
| 18682870 | METHOD FOR PRODUCING RENAL INTERSTITIAL PROGENITOR CELLS, ERYTHROPOIETIN-PRODUCING CELLS, AND METHOD FOR PRODUCING RENIN-PRODUCING CELLS | MATALKAH, FATIMAH KHALAF | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682870 | METHOD FOR PRODUCING RENAL INTERSTITIAL PROGENITOR CELLS, ERYTHROPOIETIN-PRODUCING CELLS, AND METHOD FOR PRODUCING RENIN-PRODUCING CELLS | MATALKAH, FATIMAH KHALAF | 1638 | §103§112 | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18271112 | MEDIUM FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, METHOD FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, AND METHOD FOR PRODUCING RENAL ORGANOIDS | O'NEILL, MARISOL ANN | 1633 | §102§103§112 | Final Rejection | 21d | Pending | Jul 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRege Nephro Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Fatimah Khalaf Matalkah has the most, with 1 of Rege Nephro Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
